Checkpoint Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Checkpoint Therapeutics

28/03/2022 14:06

* Checkpoint Therapeutics Inc  CKPT.OQ  reported a quarterly
adjusted loss of 39 cents​​ per share for the quarter ended in
December. The mean expectation of five analysts for the quarter
was for a loss of 15 cents per share.
    * Revenue fell 40.7% to $16.00 thousand from a year ago; 
analysts
expected $70.00 thousand. 
    * Checkpoint Therapeutics Inc's reported EPS for the quarter
was a
loss of 39 cents​.
    * The mean earnings estimate of analysts had fallen by
about 1.3%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Checkpoint Therapeutics Inc shares had fallen by 42.8%
this
quarter.
    * The company reported a quarterly loss of $29.76 million.
    * Wall Street's median 12-month price target for Checkpoint
Therapeutics Inc is $20.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 28 at 01:06 p.m.  ​All
figures in US dollars unless otherwise stated